FDA’s AI Launch, Medicare’s Tech Modernization, and New Health IT Coordinator

⁢ ⁤Updated June 04, 2025

Thomas Keane has been named Assistant Secretary for Technology Policy and national Coordinator for Health Information Technology, sources say.Keane, a‍ radiologist and former ⁢ONC advisor, assumes the role amid reorganization at the Department of Health and Human Services (HHS).

The Food and Drug Administration (FDA) has‍ initiated a broad rollout of Elsa, an agency-wide generative AI tool designed to⁣ enhance staff efficiency. The rollout follows news reports detailing the tool’s growth and employee sentiment regarding its implementation.

Meanwhile,the Centers for medicare & Medicaid Services (CMS) is advancing an ambitious tech modernization agenda,spearheaded by Amy Gleason and Arda Kara.CMS aims⁣ to demonstrate tangible progress in 2025, focusing on reengineering claims systems, launching an AI lab, and consolidating data repositories.

According to budget documents, CMS plans to leverage automation and AI to transform claims processing, enhance payment integrity, and improve data sharing across the healthcare ecosystem.

In other news, Anne Wojcicki, founder of 23andMe,⁣ is seeking to reopen the company’s ⁣auction with the backing of‍ a Fortune 500 ⁢corporation. This development follows Regeneron’s earlier declaration to acquire 23andMe ⁤out of bankruptcy.

Hims & ⁤Hers Health has announced an agreement to acquire Wonders, a European digital health company, expanding its reach into the United Kingdom, Germany, France, and Ireland.

Clairity, Inc. received FDA authorization‍ for Clairity ‍Breast, an image-based platform predicting five-year breast cancer risk from mammograms.

viz.ai is partnering with Novartis to develop AI-powered workflows for prostate and breast cancer.

IBM and roche are⁣ collaborating to provide glucose ⁣predictions for users ⁢of Roche’s Accu-Chek SmartGuide continuous glucose monitoring sensor.

What’s next

The health tech sector anticipates further developments in AI implementation, regulatory oversight, and digital health expansion as these initiatives progress.